DPP-4 inhibitor has dissociated effects on β-cell function

December 20, 2017

(HealthDay)—For healthy adults and individuals with well-controlled type 2 diabetes (T2D), a single dose of the dipeptidyl peptidase-4 inhibitor sitagliptin is associated with increased standardized insulin secretion, with no impact on β-cell glucose sensitivity, according to a study published online Dec. 11 in Diabetes, Obesity and Metabolism.

Wathik Al Salim, M.D., from Lund University in Sweden, and colleagues examined the effects of a single dose of sitagliptin on glucose-standardized and β-cell sensitivity after meal ingestion. Twelve healthy and 12 drug-naive subjects with well-controlled T2D received sitagliptin or placebo before a meal.

The researchers found that, compared with placebo, sitagliptin was correlated with increased standardized insulin secretion in healthy and T2D subjects without increasing β-cell glucose sensitivity. Increases in active glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) were also seen with , as were decreases in total GIP but not total GLP-1 levels.

"We conclude that a single dose of DPP-4 inhibition induces dissociated effects on different aspects of β-cell function and incretin hormones after meal ingestion in healthy subjects and in well-controlled T2D," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Vildagliptin, sitagliptin have similar effects on incretin

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Vildagliptin, sitagliptin have similar effects on incretin

June 20, 2016
(HealthDay)—The dipeptidyl peptidase-4 (DPP-4) inhibitors vildagliptin and sitagliptin have similar effects on incretin hormone secretion, according to a study published online June 14 in Diabetes, Obesity and Metabolism.

Beta-cell sensitivity to glucose impaired after gastric bypass

December 11, 2017
(HealthDay)—Individuals with prior Roux-en-Y gastric bypass (GB) have blunted β-cell sensitivity to changes in glycemia, according to a study published online Nov. 20 in Diabetes, Obesity and Metabolism.

Sitagliptin stimulates distal tubular natriuresis in T2DM

June 9, 2017
(HealthDay)—For patients with type 2 diabetes, the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin stimulates distal tubular natriuresis, according to a study published online May 26 in Diabetes Care.

Metformin, sitagliptin prolong normoglycemia remission in DKA

September 2, 2016
(HealthDay)—For patients with new-onset diabetic ketoacidosis (DKA) and severe hyperglycemia, metformin and sitagliptin treatment after normoglycemia remission correlate with increased relapse-free survival and prolonged ...

Dextromethorphan plus sitagliptin promising in type 2 diabetes

September 21, 2015
(HealthDay)—Dextromethorphan combined with sitagliptin shows potential for treatment of type 2 diabetes mellitus, according to a study published online Sept. 12 in Diabetes, Obesity and Metabolism.

Intestinal glucose stimulation has anti-incretin effect

September 13, 2017
(HealthDay)—Intestinal glucose stimulation has an anti-incretin effect, down regulating insulin sensitivity, according to a study published online Aug. 29 in Diabetes.

Recommended for you

Study shows drug effectiveness in reducing glucocorticoid-induced bone loss

April 25, 2018
About one in every 100 people in the world takes glucocorticoids long term to treat immune-mediated diseases. However, glucocorticoids, such as prednisone, have a side effect—they induce the bone loss called osteoporosis, ...

Implantable islet cells come with their own oxygen supply

April 25, 2018
Since the 1960s, researchers have been interested in the possibility of treating type 1 diabetes by transplanting islet cells—the pancreatic cells that are responsible for producing insulin when blood glucose concentration ...

Bariatric surgery successes lead to type 2 diabetes treatment

April 24, 2018
Bariatric surgery has long yielded almost immediate health benefits for patients with type 2 diabetes, and new findings on the reasons for remission may be the key to developing drug alternatives to surgery.

Hacking human 'drug trafficking' network could make diabetes treatments more effective

April 23, 2018
Making tiny changes to existing diabetes treatments can alter how they interact with cells, and potentially make the medicines more effective.

Vitamin D deficiency linked to greater risk of diabetes

April 19, 2018
An epidemiological study conducted by researchers at University of California San Diego School of Medicine and Seoul National University suggests that persons deficient in vitamin D may be at much greater risk of developing ...

One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo

April 17, 2018
One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo, suggests new findings.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.